EZH2 and ovarian carcinoma: One study found that miR-101 and miR-26a may target the enhancer of the zeste homolog 2 (EZH2)-Notch signaling pathway and decrease T cell aerobic glycolysis, thereby reducing tumorigenesis in ovarian cancer (51).